INO

INO

Internuclear ophthalmoplegia (INO) is a neurologic ocular motility disorder characterized by impaired horizontal eye movement due to lesions of the medial longitudinal fasciculus. It commonly appears in association with demyelinating diseases, cerebrovascular events, and brainstem lesions, and is frequently described in clinical neurology, neuro-ophthalmology, and neuroradiology literature. Classic signs include adduction deficit of the ipsilateral eye and abducting nystagmus of the contralateral eye, often elicited during attempted lateral gaze.

Definition and Overview

INO denotes a lesion of the medial longitudinal fasciculus within the dorsal pontine or midbrain tegmentum, disrupting internuclear connections between the abducens nucleus in the pons and the oculomotor nucleus in the midbrain. Descriptions of INO appear in case series from institutions such as Mayo Clinic, Johns Hopkins Hospital, and publications from American Academy of Neurology and American Academy of Ophthalmology. Classic neurological syndromes co-occurring with INO include presentations documented in Multiple sclerosis cohorts, Pontine infarction registries, and reports following traumatic brain injury or brainstem glioma resection. Imaging correlates are commonly reported in studies from centers like Massachusetts General Hospital and Mount Sinai Medical Center.

Causes and Pathophysiology

INO arises from focal disruption of axonal pathways within the medial longitudinal fasciculus due to demyelination, ischemia, compression, infection, or neoplasm. In younger adults, lesions are frequently due to Multiple sclerosis plaques located near the periaqueductal gray or dorsal pontine tegmentum; in older patients, arterial occlusion such as Pontine infarction from Basilar artery atherothrombosis or lacunar stroke is a principal cause. Tumors including Brainstem glioma and metastatic lesions described in oncology case reports can compress the fasciculus, while infectious etiologies like Listeria monocytogenes rhombencephalitis and paraneoplastic syndromes associated with Small-cell lung carcinoma have been reported. Pathophysiologically, interruption of excitatory and inhibitory internuclear fibers prevents coordination between the Abducens nucleus and Oculomotor nucleus, producing the hallmark dissociation between abduction and adduction; associated lesions may involve adjacent structures such as the Pineal region, Superior cerebellar peduncle, or the periventricular white matter seen in Magnetic resonance imaging studies.

Clinical Presentation and Diagnosis

Patients with INO present with horizontal diplopia, slowed adduction, and contralateral abducting nystagmus on lateral gaze; bilateral INO patterns appear in case series of Multiple sclerosis patients and central pontine myelinolysis cohorts. Examination maneuvers referenced in textbooks from Oxford University Press and clinical manuals from Cleveland Clinic include bedside saccade testing, cover-uncover tests, and assessment for convergence sparing, which helps distinguish INO from peripheral cranial nerve palsies such as isolated III cranial nerve palsy or VI cranial nerve palsy. Neuroimaging with Magnetic resonance imaging—including diffusion-weighted imaging and T2/FLAIR sequences—identifies demyelinating plaques or ischemic lesions; contrast-enhanced MRI and magnetic resonance angiography performed at institutions like Stanford Health Care and UCLA Health can reveal inflammatory or vascular etiologies. Ancillary testing may include lumbar puncture with oligoclonal band analysis in suspected Multiple sclerosis from centers like Karolinska Institutet and evoked potentials referenced by World Health Organization neurological protocols.

Management and Treatment

Treatment of INO targets the underlying cause and symptomatic rehabilitation. In demyelinating cases, acute management often follows protocols using high-dose corticosteroids as practiced at Mayo Clinic and disease-modifying therapies from trials by National Multiple Sclerosis Society collaborators such as Biogen, Roche, and Novartis. Ischemic INO management aligns with stroke pathways including thrombolysis or secondary prevention per American Heart Association and American Stroke Association guidelines, addressing risk factors like Hypertension and Atherosclerosis managed by cardiology services at major centers. Symptomatic therapies include prism lenses prescribed by neuro-ophthalmology clinics at Johns Hopkins Hospital and botulinum toxin injections in selected cases described in surgical series from Cleveland Clinic. Rehabilitation modalities—oculomotor exercises, vestibular therapy, and neuro-visual training—are implemented in tertiary centers such as Spaulding Rehabilitation Hospital and Shepherd Center for functional recovery.

Prognosis and Complications

Prognosis of INO depends on etiology: demyelinating INO associated with Multiple sclerosis may show partial or complete recovery over weeks to months, whereas ischemic INO following Pontine infarction often yields more persistent deficits, as reported in longitudinal studies from European Stroke Organisation investigators. Bilateral INO and associated brainstem signs predict greater disability, and complications include chronic diplopia, impaired gaze conjugacy, and reduced quality of life necessitating multidisciplinary care from neuro-ophthalmology, neurology, and rehabilitation medicine teams at institutions like Massachusetts Eye and Ear and Royal London Hospital. Long-term management may involve coordination with rehabilitation programs and, when indicated, neurosurgical or interventional radiology consultations for mass lesions or vascular malformations.

Category:Neurological disorders